Tagged with Taiwan

Taiwan Taiwan, an early international market for Kyowa Kirin, now serves as a strategic hub within a Korea-Taiwan-Australia cluster. With a lean team, close government engagement, and clinical trial initiatives, Taiwan General Manager Tatsuru Iwamoto outlines his affiliate’s portfolio prioritisation, collaboration, and life-changing value delivery while leveraging Taiwan’s policy strengths and…

Taiwan Professor Chi-Huey Wong serves as President of the Institute for Biotechnology and Medicine Industry (IBMI) in Taiwan, bringing decades of distinguished experience from top-tier US research institutions including MIT, Scripps Research and his tenure as President of Academia Sinica. With a unique vantage point spanning both American and Taiwanese scientific…

Taiwan Built around an engineering mindset and a clear view of where a smaller biotech can compete, Pharmosa is pursuing a differentiated path in pulmonary hypertension and related rare diseases through drug-device combination therapies. In this discussion, Pei Kan outlines how scientific focus, selective partnerships, disciplined capital allocation, and early investment…

Taiwan Pei-Jiun Chen, CEO and President of Mycenax, outlines the company’s evolution into a focused, end-to-end biologics CDMO with deep roots in development excellence and GMP manufacturing. She highlights Japan as Mycenax’s core market, expansion into Europe, disciplined capacity growth, automation-driven productivity, and a niche, customer-centric model supporting complex biologics and…

Taiwan With over two decades of global pharmaceutical experience at Eli Lilly and Allergan, Dr Jimmy Chang returned to Taiwan to lead TaiMed Biologics, Taiwan’s first biotech to successfully commercialise a biologic therapy worldwide. Now CEO, Chang has overseen the company’s evolution from a single-asset HIV specialist to a globally recognised…

Taiwan Will Hsu leads Sandoz operations across Taiwan, Hong Kong, and Macao, managing a portfolio spanning both generics and biosimilars in markets characterised by universal healthcare and significant budget constraints. With nearly 12 years at Sandoz, including three years in his current regional role, Hsu oversees strategic initiatives to increase biosimilar…

Taiwan Taiwanese biotech Caliway is trying to redefine fat reduction as measurable medicine. Founded in 2012, Caliway has advanced its first-in-class candidate CBL-514 into pivotal Phase III development in the US, following ten completed clinical studies. President Antony Hsu outlines the science behind selective adipocyte apoptosis, the regulatory strategy behind the…

Taiwan Frederic Kuo, founder and CEO of Fethiann, established the company in 2017 within Taiwan’s Hsinchu Science Park. With a PhD background and extensive experience in new drug development, Frederick has positioned Fethiann as Taiwan’s sole specialist in natural phytochemical active pharmaceuticals. The company’s unique business model integrates Active Phytochemicals Ingredient…

Taiwan Sean Chang, CEO of Locus Cell, explains how his clinical CAR-T background led him to build a Taiwan-based CDMO for advanced cell therapies. The company is scaling Southeast Asia’s largest GMP facility, leveraging Taiwan’s manufacturing discipline, regulatory reforms and global partnerships to deliver high-quality, cost-competitive production bridging academic innovation and…

Taiwan In 2024, Taipei Medical University reached a defining milestone. President Mai-Szu Wu oversaw a full digital transformation linking seven affiliated medical institutions and more than 3,000 beds into a unified data platform, creating a foundation for large-scale research, AI applications, and faster clinical-trial operations. This momentum has now extended nationwide…

Taiwan Jayashri Kulkarni Managing Director of Johnson & Johnson Taiwan, brings 27 years of experience across pharmaceuticals and medical technology in Asia Pacific. Since assuming her Taiwan role , she has focused on outcome-based healthcare, patient advocacy, and leadership development, bringing a perspective that bridges emerging market innovation with healthcare system…

Taiwan With Takeda preparing for global leadership change and Taiwan rapidly upgrading its innovation and access frameworks, General Manager Alexis Lin is navigating one of the most pivotal periods in the affiliate’s 64-year history. Drawing on a career that began far from pharma, she has reshaped Takeda Taiwan into a regional…